{
  "docId": "019de076-7d6c-774e-85e8-ffe50da37251",
  "docSlug": "0b0d701714d17efa78c23c196990e90c",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 37,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7d6c-774e-85e8-ffe50da37251/16",
  "deckHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251",
  "deckJsonHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251.json",
  "deckAnchorHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.2,
        "y": 0.78
      },
      "kind": "callout",
      "text": "A platinum resensitizing agent is a long-standing desirable and highly demanded mechanism of action of Gyn-Oncs, their so-call “Holy Grail”.*",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c48cfd1-29c9-4a7c-b31c-4715bef5f486",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.29,
        "y": 0.29
      },
      "kind": "diagram",
      "text": "Multi-center, randomized open-label n=186. Experimental Arm: Olvi-Vec + Platinum-doublet + Bevacizumab. Active Comparator Arm: Platinum-doublet + Bevacizumab. Topline results expected in 2H, 2025",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bba7679-064a-4581-b5f4-6cd1def06468",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.26,
        "x": 0.02,
        "y": 0.3
      },
      "kind": "list",
      "text": "Key Inclusion Criteria: High-grade serous, endometrioid, or clear-cell ovarian cancer; Platinum-resistant or -refractory disease; Received prior bevacizumab; 3+ prior lines of therapy; ECOG 0-1; Life expectancy 6+ months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c2cc2de-f097-471a-be34-f3e51bfecd6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99bc77a7-53b6-4926-a395-5d87ed8f7579",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.32,
        "x": 0.67,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*Journal of Investigative Medicine High Impact Case Reports, Volume 6: 1–3, 2018 DOI: 10.1177/2324709618760080 J ournals.sagepub.com/home/hic",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "221b00a5-c814-4c82-99ce-e4571313f2ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.73,
        "y": 0.29
      },
      "kind": "table",
      "text": "Primary Endpoint: Progression-Free Survival. Key Secondary Endpoints: 1. Treatment-emergent AEs, 2. Duration of Response (DOR), 3. Overall Response Rate (ORR), 4. Overall Survival (OS)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a79f2e1-4221-40e7-b779-eac7eafc8a25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43bc8899-629a-40b5-b33a-5c6b473f23c1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "8c91d67d-64c1-48d0-b24f-7d30a5a5a39e",
      "evidence": "table/data: Primary Endpoint: Progression-Free Survival. Key Secondary Endpoints: 1. Treatment-emergent AEs, 2. Duration of Response (DOR), 3. Overall Response Rate (ORR), 4. Overall Survival (OS)",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}